Alnylam Pharmace. sell dimontalban
Start price
21.08.22
/
60%
€214.90
Target price
21.08.23
€87.00
Performance (%)
-3.44%
End price
04.09.22
€207.50
Summary
This prediction ended on 04.09.22 with a price of €207.50. With a performance of -3.44%, the SELL prediction by dimontalban was trending in the right direction. dimontalban has 60% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 5.228% | 5.228% | -25.629% |
| iShares Core DAX® | 3.178% | 0.980% | 15.331% |
| iShares Nasdaq 100 | 2.972% | 0.925% | 39.831% |
| iShares Nikkei 225® | 0.545% | -4.556% | 17.661% |
| iShares S&P 500 | 2.367% | 0.833% | 30.000% |
According to dimontalban what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Standard Investments for future growth
Capable Management
Very good company culture
Innovative
Some uniques
Differentiated customer and product portfolio
Sustainability is important
Stable Large shareholder and/or long term investor
Top 10 in its market
Known brand
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
very negative Cash Flow expected
Junk rating
High risks in the balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Growths slower than the competition
High risks for its business
Very high cyclical dependencies
Outdated or very high risk business model
Comments by dimontalban for this prediction
In the thread Alnylam Pharmace. diskutieren
Sell mit Kursziel 87,0